Hillstream BioPharma, Inc. (HILS)
Company Description
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers.
The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.
The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jan 12, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Mr. Randy D. Milby MBA |
Contact Details
Address:
1200 Route 22 East Bridgewater, New Jersey 08807 United States | |
| Phone | 302-743-2995 |
| Website | hillstreambio.com |
Stock Details
| Ticker Symbol | HILS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001861657 |
| CUSIP Number | 432705101 |
| ISIN Number | US4327051011 |
| Employer ID | 84-2642541 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Randy D. Milby MBA | President, Chairman and Chief Executive Officer |
| Thomas P. Hess CPA, MBA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2022 | 10-Q | Quarterly Report |
| Oct 28, 2022 | 8-K | Current Report |
| Aug 11, 2022 | 10-Q | Quarterly Report |
| Aug 9, 2022 | 8-K | Current Report |
| Jun 23, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 17, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 17, 2022 | DEF 14A | Other definitive proxy statements |
| May 16, 2022 | 10-Q | Quarterly Report |
| Apr 1, 2022 | 10-K | Annual Report |
| Apr 1, 2022 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |